Modification of Vegetable Proteins to Release Bioactive Peptides Able to Treat Metabolic Syndrome—In Silico Assessment

Diego Armando Maldonado-Torres 1, D. Alejandro Fernández-Velasco 2, Gema Morales-Olán 1, F. Fatima Rosas-Cardenas 1 and Silvia Luna-Suárez 1,*

1 Centro de Investigación en Biotecnología Aplicada, Instituto Politécnico Nacional, CIBA-IPN, Carretera estatal Tecuexcomac-Tepetitla Km. 1.5, Tepetitla 90700, Tlaxcala, Mexico; darmanmalto@gmail.com (D.A.M.-T.); morales.gema13@gmail.com (G.M.-O.); frosasc@ipn.mx (F.F.R.-C.)
2 Laboratorio de Fisicoquímica e Ingeniería de Proteínas, Departamento de Bioquímica, Facultad de Medicina, UNAM, Ciudad de México 04510, Mexico; fdaniel06@gmail.com
* Correspondence: silvials2004@yahoo.com.mx or sluna@ipn.mx; Tel.: +52-55-729-6300 (ext. 87814)

Received: 12 February 2020; Accepted: 5 April 2020; Published: 10 April 2020

Featured Application: This work introduces a novel way of designing proteins for the treatment of diseases, especially metabolic syndrome.

Abstract: Metabolic syndrome comprises a cluster of diseases like hypertension, dyslipidemia, and insulin resistance, among others. Its treatment is based on lifestyle modification; however, this treatment often fails to improve metabolic syndrome indicators over the long term. In this work, sequences of some representative vegetable proteins were explored to find bioactive peptides with activity toward metabolic disorders of metabolic syndrome. Five proteins, i.e., legumin (chickpea), glutelin type A-2 (chickpea), glutelin type B-2 (rice), prolamin PPROL 17 (maize), and glutelin (rice) revealed a high potential to be effective against metabolic syndrome. We designed and evaluated in silico modifications to their amino acid sequence to release bioactive peptides after simulating gastrointestinal digestion (SGD). The approach presented here allows the design of proteins that could combat metabolic syndrome, for later production and study. In the future, these proteins can be used as functional foods.

Keywords: metabolic syndrome; bioactive peptides; storage proteins; in silico design

1. Introduction

Metabolic syndrome is a cluster of metabolic disturbances that increase the risk of stroke and cardiovascular diseases (CVD). Obesity, hypertension, insulin resistance, and dyslipidemias are the principal components of metabolic syndrome [1]. This syndrome affects pediatric populations [2] as well as older people [3] and is a public health issue. The current treatment is based on lifestyle interventions, particularly by modification of the diet and an increase in physical activity to prevent cardiovascular complications [4]. Drugs can also be used to treat unique components of the syndrome [5]. The principal aim of treatment is to prevent or delay the complications of CVD, but this primary intervention is only effective for weight control [6].

An alternative metabolic syndrome treatment is the use of bioactive peptides—short sequences of amino acids that improve human health. These peptides can be released from both animal and vegetable proteins, and more than 1500 sequences have been reported [7]. Bioactive peptides have shown multiple beneficial effects on human health such as antihypertensive, antidiabetic, antimicrobial, immunomodulatory, anti-cancer, lipid-lowering, antioxidant effects, and dipeptidyl-peptidase 4...
(DPPIV) inhibition. Some of these are useful in the treatment of metabolic syndrome [8,9], so bioactive peptides or proteins that contain these peptides can be part of functional foods [10].

In silico analysis is a valuable tool for predicting specific functions and/or for establishing strategies to deliver bioactive peptides from proteins. For example, Lin et al. [11] analyzed αs1, αs2, β, and κ-casein from yak milk and found that these proteins have peptidic fragments in their sequence with reported biological activity, like angiotensin-converting-enzyme inhibitors (ACEI) and DPPIV inhibitors. They proposed a strategy to release them with a tandem digestion; similarly, Fu et al. [12] evaluated the potential of releasing bioactive peptides from patatin after in silico digestion with different proteases and they found multiple fragments with ACEI and DPPIV activity.

Bioactive peptides can be obtained by chemical synthesis; nevertheless, the production process can be non-viable [13]. Two principal methods are used to produce bioactive peptides. In the first, a protein or protein mixture is subjected to hydrolysis with one or more proteolytic enzymes. The other production method is microbial fermentation and involves the use of bacteria or yeast, rather than pure or crude enzymes, to hydrolyze proteins in the culture broth [8]. In both cases, the starting material to be hydrolyzed consists of food proteins. Clearly, the amount and type of bioactive peptides than can be obtained by such methods are determined by the amino acid sequences of the starting material. Here, we propose the use of protein engineering methods to increase the number and diversity of bioactive peptides that can be obtained via the hydrolysis of a particular protein. To do this, we first defined a set of bioactive peptides that can treat metabolic syndrome. We then evaluated a group of representative vegetable proteins to determine the number and type of bioactive peptides included in their natural sequences. Considering that plants provide approximately 58% of proteins that humans consume [14], seeds are the main source of protein consumed by humans [15]. Interestingly, proteins from plants are associated with a lower incidence of CVD [16]. Thus, seed storage proteins were appraised in this work. We later designed mutations to increase the number and type of bioactive peptides. Finally, we evaluated the digestion patterns of the modified proteins in silico. These proteins can be produced by heterologous expression in bacteria or yeast.

2. Materials and Methods

2.1. Bioactive Peptides Selection

ACEI peptides and inhibitors of DPPIV peptides were selected from the BIOPEP database [17]; only di- and tripeptides were selected. These peptides were sorted on the basis of their reported IC50, and those peptides with in vivo activity were given priority. Antioxidant and lipid-lowering peptides were searched and selected based on the literature. To evaluate resistance to gastrointestinal enzymes, the selected peptides were submitted to in silico gastrointestinal digestion with BIOPEP and PeptideCutter tools, choosing pepsin pH 1.3, trypsin, and chymotrypsin.

2.2. Scaffold Selection

The sequences of some representative seed storage proteins were obtained from the UniProt Database to identify the previously selected peptides; protein sequences were scanned, and their potential to treat metabolic syndrome was evaluated with the parameter A, defined as:

\[ A = \frac{a}{N} \]

Here, A is the relative frequency of bioactive peptides able to treat metabolic syndrome, a is the number of selected bioactive peptides, and N is the sequence length.

2.3. Protein Design

To design proteins capable of treating metabolic syndrome, we considered the specificities of gastrointestinal enzymes such as pepsin, trypsin, and chymotrypsin. We then proposed modifications
to their amino acid sequences to release the selected peptides after simulating gastrointestinal digestion. The in silico peptide profiles of modified proteins were then compared with those of the native ones after digestion with the aforementioned enzymes. To design the proteins, sequences were used without the signal peptide.

2.4. In Silico Evaluation

The modified proteins were evaluated by the Peptide Cutter tool to determine the release of the biopeptides; protein toxicity was evaluated using the ToxinPred tool (Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh, India, 2013) available in http://crdd.osdd.net/raghava/toxinpred/ with default options [18].

3. Results and Discussion

3.1. Peptides to Treat Metabolic Syndrome

Proteins from foods are digested in the gastrointestinal tract by multiple proteases. Total protein is digested to di- and tripeptides before being absorbed by small intestine cells. Only 10% of the protein remains as di- and tripeptides after digestion by peptidases of the brush border and enterocytes [19]. Thus, we only considered peptides with a maximum length of three amino acids to construct a protein that can release these peptides. The BIOPEP database showed 258 ACEI peptides and 287 DPPIV inhibitor peptides. These peptides were sorted according to their IC$_{50}$ and evaluated in gastrointestinal digestion (SGD). ACEI peptides that showed resistance to SGD and presented the highest activity were selected. These were IW (isoleucine-tryptophan), VY (valine-tyrosine), IY isoleucine-tyrosine, EY (glutamate-tyrosine), and DG (aspartate-glycine). Except for EY, all peptides presented in vivo activity despite being hydrophobic [20–23]. These have been described as unstable during gastrointestinal digestion [24]. For protein design, we selected the tripeptide IPI (isoleucine-proline-proline) as a DPPIV inhibitor because it is the most powerful peptide against this enzyme [25]. Based on the review by Nogonierma [26], the antioxidant dipeptide CG [27] and the lipid-lowering dipeptide DE [28] were also chosen as potential peptides against metabolic syndrome (Table 1). Iwaniak [9] also recently reviewed peptides with the potential to treat metabolic syndrome, including the aforementioned peptides. This work suggests that the dipeptides IY and VY are potential peptides to treat hypertension in metabolic syndrome. Most of the selected peptides considered for protein design are uncharged or hydrophobic. This could favor their bioavailability and absorption through the transporter PepT1 and paracellular transport [29].

| Peptide | Activity | IC50 (µM) | In Vivo | Reference |
|---------|----------|-----------|---------|-----------|
| VY      | ACEI     | 7.1       | ✓       | [30]      |
| VW      | ACEI     | 1.4       | x       | [31]      |
| IW      | ACEI     | 4.7       | ✓       | [20]      |
| IY      | ACEI     | 2.69      | ✓       | [32]      |
| EY      | ACEI     | 2.68      | x       | [33]      |
| DG      | ACEI     | 12.3      | ✓       | [22]      |
| IPI     | DPPIV Inhibitor | 1.1 µg/ml | x | [26] |
| GW      | Antioxidant | -        | x       | [34]      |
| DW      | Antioxidant | -        | x       | [35]      |
| CG      | Antioxidant | -        | x       | [24]      |
| DE      | Lipid-lowering | - | ✓       | [28]      |

In vivo: ✓ Indicates peptides with a reported in vivo activity; x indicates no reported in vivo activity. ACEI, angiotensin-converting-enzyme inhibitors, DPPIV, dipeptidyl-peptidase 4.
3.2. Scaffold Selection

We obtained 41 sequences of seed storage proteins from different vegetables from the Uniprot Database. To evaluate their therapeutic potential, the amino acid sequences of the selected bioactive peptides were searched (Table 2). The protein with the highest number of selected peptides (11) was rice glutelin (Q6T725). Higher $A$ values were found for rice glutelin Q6T725 (0.023), chickpea legumin (Q9SMJ4) (0.021), chickpea glutelin A-2 (A0A1S2YJV5) (0.03), maize prolamin PPROL 17 (B6UH22) (0.024), and rice glutelin B-2 (Q02897) (0.021).

The highest $A$ value was found in chickpea glutelin A-2 and maize prolamin PPROL 17; however, these proteins had the lowest number of selected peptides, six and four, respectively. Their high $A$ value is a consequence of a lower number of amino acids. The five proteins selected as scaffolds contain peptides with ACEI activity—all of them present the dipeptide VY, except chickpea legumin. This VY dipeptide is the most studied antihypertensive peptide and has in vivo activity [22]. Maize prolamin PPROL 17 is the only protein containing the antioxidant peptide CG. The DE lipid-lowering peptide was found in three of the selected proteins, in particular, in chickpea legumin, where it was found seven times. Thus, this protein can offer lipid-lowering activity after modifications. None of the selected proteins contain the DPPIV inhibitor peptide IPI.

3.3. In Silico Design of a Protein against Metabolic Syndrome

Five of the selected proteins were then analyzed by the SGD with the PeptideCutter tool, as described in the Materials and Methods section. Despite the fact that each protein has multiple hydrolysis sites for the enzymes employed, only four of the selected peptides were released: one from rice glutelin, one from chickpea glutelin A-2, and two from rice glutelin B-2. In all cases, the released peptide was the ACEI peptide VY. To facilitate the release of the peptides of interest, we leveraged the specificities of digestive enzymes and designed linker sites substituting amino acids with Phe, which is hydrolyzed at the C-terminus, or Leu, which is hydrolyzed at both the C-terminus and the N-terminus (Figure 1). These substitutions affected residues adjacent to the peptides of interest. Arg and Lys were used as linkers in the N-terminus to substitute hydrophilic or charged amino acids.

Chickpea legumin has two DEDEDE hexapeptides in positions 251–256 and 267–272. Here, the proposed modifications were the addition of Leu between each DE repeat. As expected, each of the peptides were released subsequent to SGD after the proposed modifications (Table 3). The rice glutelin residues 244–246 are DEY, and the dipeptides DE and EY are both present in this sequence. We designed a site to release the DE dipeptide because of the high number of ACEI peptides found in this protein.

Pooj [35] reported that glutelin type A-1 releases multiple ACEI peptides after pepsin digestion; this protein has 95% identity with glutelin type A-2 analyzed here. For none of the other proteins investigated, biological activity predictions derived from bioactive peptides have been published. To the best of our knowledge, this is the first work that proposes modification of proteins to release bioactive peptides after oral ingestion. This can enhance and/or provide specific biological activity to proteins in addition to their nutritional value. Toxicity analyses did not show sequences or motifs indicating toxicity after the proposed substitutions.

This work reports a new approach for the use of bioactive peptides as an alternative treatment for metabolic syndrome. Further experimental confirmation is required, because proteolytic enzymes do not always behave as expected. This type of analysis speeds up the design of therapeutic proteins or released peptides. To the best of our knowledge, there are no reported cases of proteins designed with the ability to treat or prevent metabolic syndrome.
Table 2. Frequency of the selected bioactive peptides in vegetable proteins and their A number (relative frequency of bioactive peptides able to treat metabolic syndrome).

| Protein Type                  | Uniprot Entry | Sequence Length | IW | VW | VY | IY | EY | DG | IPI | GW | CG | DW | DE | Total | A   |
|------------------------------|---------------|-----------------|----|----|----|----|----|----|-----|----|----|----|----|-------|-----|
| Soy                          |               |                 |    |    |    |    |    |    |     |    |    |    |    |       |     |
| β-conglucinin chain alfa     | P11827        | 617             | 0  | 0  | 0  | 1  | 0  | 0  | 0   | 0  | 6  | 7  | 0   | 0.011 |
| β-conglucinin chain beta     | P25974        | 426             | 0  | 0  | 0  | 1  | 0  | 0  | 0   | 0  | 2  | 3  | 0.007|
| Albumin 2S                   | P19594        | 137             | 0  | 0  | 0  | 0  | 0  | 0  | 0   | 0  | 2  | 2  | 0.015|
| Basic 7S Globulin            | P13917        | 403             | 0  | 1  | 1  | 0  | 1  | 1  | 0   | 1  | 0  | 5  | 0.012|
| Amaranth                     |               |                 |    |    |    |    |    |    |     |    |    |    |    |       |     |
| 11S Globulin                 | Q38712        | 501             | 0  | 1  | 1  | 2  | 1  | 1  | 0   | 0  | 2  | 8  | 0.016|
| Oat                          |               |                 |    |    |    |    |    |    |     |    |    |    |    |       |     |
| Avenin 3                     | P80356        | 201             | 0  | 0  | 1  | 0  | 0  | 0  | 0   | 0  | 0  | 1  | 0.005|
| 11S Globulin                 | Q38780        | 503             | 0  | 2  | 2  | 1  | 1  | 0  | 0   | 0  | 2  | 8  | 0.016|
| Beans                        |               |                 |    |    |    |    |    |    |     |    |    |    |    |       |     |
| Phaseolin                    | P80463        | 404             | 0  | 2  | 1  | 0  | 0  | 0  | 0   | 0  | 0  | 3  | 0.007|
| Globulin-1                   | A6YNT0        | 224             | 0  | 0  | 0  | 1  | 0  | 0  | 1   | 0  | 0  | 2  | 0.012|
| Alpha-zein 16                | P04700        | 242             | 0  | 1  | 0  | 0  | 0  | 0  | 0   | 0  | 0  | 1  | 0.004|
| Gamma-zein                   | C0P381        | 267             | 0  | 0  | 1  | 0  | 0  | 0  | 0   | 2  | 0  | 3  | 0.011|
| Rice                         |               |                 |    |    |    |    |    |    |     |    |    |    |    |       |     |
| Prolamin PPROLINE 4E         | Q0D4J5        | 131             | 0  | 1  | 0  | 1  | 0  | 0  | 0   | 0  | 0  | 2  | 0.015|
| Cupincin                     | B8AL97        | 436             | 0  | 0  | 1  | 0  | 1  | 0  | 0   | 0  | 5  | 7  | 0.016|
| Globulin                     | P29835        | 164             | 0  | 0  | 0  | 0  | 1  | 0  | 0   | 1  | 0  | 0  | 2   | 0.013|
| Glutelin                     | Q61725        | 471             | 0  | 3  | 1  | 2  | 2  | 0  | 0   | 0  | 0  | 3  | 0.023|
| Glutelin Type A-2            | P07730        | 475             | 0  | 3  | 1  | 0  | 1  | 0  | 0   | 0  | 0  | 3  | 0.017|
| Glutelin Type B-2            | Q02897        | 481             | 0  | 4  | 1  | 2  | 0  | 0  | 0   | 2  | 10 | 0.021|
| Maize                        |               |                 |    |    |    |    |    |    |     |    |    |    |    |       |     |
| Globulin-1 S Allele          | P15590        | 487             | 0  | 0  | 0  | 0  | 0  | 1  | 0   | 0  | 0  | 2  | 3   | 0.006|
| 22 kDa alpha zein 4          | O48966        | 245             | 0  | 0  | 0  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0.000|
| 50 kDa gamma zein            | C0P381        | 267             | 0  | 0  | 0  | 0  | 1  | 0  | 0   | 0  | 2  | 0   | 0.011|
| Globulin-2                   | Q7M1Z8        | 431             | 0  | 0  | 0  | 0  | 1  | 0  | 0   | 0  | 0  | 3  | 0   | 0.009|
| Globulin-1                   | A6YNT0        | 221             | 0  | 0  | 0  | 0  | 0  | 1  | 0   | 0  | 0  | 2  | 3   | 0.013|
| 18 kD delta zein             | Q946V9        | 190             | 0  | 0  | 0  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0   | 0.000|
| Prolamin PPROL 17            | B6UH22        | 164             | 0  | 0  | 0  | 0  | 1  | 0  | 0   | 0  | 3  | 0   | 0.024|
| Chickpea                     |               |                 |    |    |    |    |    |    |     |    |    |    |    |       |     |
| Legumin                      | Q9SMJ4        | 475             | 1  | 0  | 0  | 1  | 0  | 1  | 0   | 0  | 0  | 7  | 10  | 0.021|
| Globulin-1 S Allele          | A0A1S2YZ56    | 621             | 0  | 0  | 0  | 1  | 1  | 2  | 0   | 1  | 1  | 0  | 3   | 0.014|
| 11S Globulin seed storage    | A0A1S2YG7T3   | 348             | 1  | 1  | 2  | 0  | 2  | 0  | 0   | 0  | 1  | 7  | 0.020|
Table 2. Cont.

| Protein                                      | Uniprot Entry | Sequence Length | IW | VW | VY | IY | EY | DG | IPI | GW | CG | DW | DE | Total | A   |
|----------------------------------------------|---------------|-----------------|----|----|----|----|----|----|-----|----|----|----|----|-------|-----|
| Glutelin Type-A 2-Like                       | A0A1S2Y JV5   | 200             | 0  | 1  | 1  | 0  | 0  | 4  | 0   | 0  | 0  | 0  | 0  | 6     | 0.030|
| Lentil                                        | P86782        | 37              | 0  | 0  | 0  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 0     | 0.000|
| Lentil Albumin S                              | P08438        | 436             | 0  | 0  | 0  | 1  | 2  | 0  | 0   | 0  | 0  | 0  | 0  | 2.5   | 0.011|
| Broad Bean Legumin type B                     | P08438        | 436             | 0  | 0  | 0  | 2  | 2  | 1  | 0   | 0  | 0  | 0  | 0  | 1     | 0.013|
| Broad Bean Vicilin                            | P05190        | 462             | 0  | 0  | 0  | 1  | 2  | 0  | 0   | 0  | 0  | 0  | 0  | 2     | 0.011|
| Broad Bean Convicilin                         | B0BCL8        | 469             | 0  | 0  | 0  | 0  | 1  | 0  | 0   | 0  | 0  | 0  | 0  | 4     | 0.011|
| Wheat Glutenin subunit DX5                   | P10388        | 827             | 0  | 0  | 0  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 0     | 0.000|
| Wheat Avenin-like B1                          | Q2A783        | 267             | 0  | 0  | 0  | 2  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 2     | 0.007|
| Wheat Alpha/Beta Gliadin                      | P02863        | 266             | 0  | 0  | 1  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 1     | 0.004|
| Wheat Alpha/Beta Gliadin A-I                  | P04721        | 242             | 0  | 0  | 0  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 0     | 0.000|
| Wheat Alpha/Beta Gliadin A-II                 | P04722        | 271             | 0  | 0  | 1  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 1     | 0.004|
| Wheat Alpha/Beta Gliadin A-III                | P04723        | 262             | 0  | 0  | 1  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 1     | 0.004|
| Wheat Alpha/Beta Gliadin A-IV                 | P04724        | 277             | 0  | 0  | 1  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 1     | 0.004|
| Wheat Alpha/Beta Gliadin A-V                  | P04725        | 299             | 0  | 0  | 1  | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 1     | 0.003|
| Glutelin Type A-1                             | M7ZVJ6        | 299             | 0  | 1  | 0  | 0  | 0  | 3  | 0   | 0  | 1  | 1  | 0  | 6     | 0.020|
Figure 1. Sequences of (A) rice glutelin Q6T725, (B) chickpea legumin Q9SMJ4, (C) chickpea glutelin type B-2 Q02897, (D) chickpea glutelin type A-2 A0A1S2YJV5, and (E) maize prolamin PPROL 17 B6UH22 and their modifications. The gray squares indicate selected bioactive peptides, and the arrows indicate modifications in the amino acid sequences.

Table 3. Number of peptides released after modifications.

| Protein                  | Number of Cleavage Sites | Fragments         | Selected Peptides Released |
|--------------------------|--------------------------|-------------------|---------------------------|
|                           | Native | Modified | Native | Modified | Native | Modified |
| Glutelin Q6T725           | 160    | 182      | 144    | 160      | 1      | 8        |
| Legumin Q9SMJ4            | 192    | 206      | 167    | 180      | 0      | 10       |
| Glutelin type-A 2 A0A1S2YJV5 | 143    | 154      | 123    | 134      | 1      | 6        |
| Prolamin PPROL 17 B6UH22  | 42     | 49       | 39     | 47       | 0      | 4        |
| Glutelin type-B 2 Q02897  | 165    | 179      | 144    | 159      | 2      | 9        |
4. Conclusions

The dipeptides identified in the natural proteins reported here are not released after a simulated gastrointestinal digestion. This suggests they would not treat metabolic syndrome. After the design proposed here, rice glutelin type B-2 appears as the best option to treat metabolic syndrome. Chickpea legumin, after the modifications proposed here, appears as an option to diminish cholesterol. The approach described here can facilitate the design of proteins that could combat metabolic syndrome. These proteins can be produced by heterologous expression in bacteria or yeast; in the long term, they could be produced in transgenic plants. These recombinant proteins can be added to food matrices.

Author Contributions: Conceptualization, S.L.-S.; D.A.F.-V. and D.A.M.-T.; methodology, D.A.M.-T.; validation, S.L.-S. and D.A.F.-V.; formal analysis, D.A.M.-T.; investigation, S.L.-S. and D.A.M.-T.; resources, S.L.-S.; writing—original draft preparation, D.A.M.-T.; writing—review and editing, D.A.M.-T.; D.A.F.-V.; G.M.-O. and F.F.R.-C.; supervision, S.L.-S. All authors have read and agreed to the published version of the manuscript.

Acknowledgments: We thanks the Secretaría de Investigación y Posgrado-IPN and Consejo Nacional de Ciencia y Tecnología (CONACYT) for the scholarship to Maldonado-Torres.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Grundy, S.M. Metabolic syndrome update. *Trends Cardiovasc. Med.* 2016, 26, 364–373. [CrossRef] [PubMed]
2. Mameli, C.; Zuccotti, G.V.; Carnovale, C.; Galli, E.; Nannini, P.; Cervia, D.; Perrotta, C. An update on the assessment and management of metabolic syndrome, a growing medical emergency in pediatric populations. *Pharmacol. Res.* 2017, 119, 99–117. [CrossRef] [PubMed]
3. Domínguez, L.J.; Barbagallo, M. The biology of the metabolic syndrome and aging. *Curr. Opin. Clin. Nutr. Metab. Care* 2015, 19, 5–11. [CrossRef] [PubMed]
4. Alberti, K.; Zimmet, P.; Shaw, J. Metabolic syndrome—A new worldwide definition. *Diabetic Med.* 2006, 23, 469–480. [CrossRef]
5. Wagh, A.; Stone, N.J. Treatment of metabolic syndrome. *Expert Rev. Cardiovasc. Ther.* 2014, 2, 213–228. [CrossRef]
6. Ilanne-Parika, P.; Toumilehto, J. Lifestyle Intervention of Complications to the Metabolic Syndrome. In *The Metabolic Syndrome*; Beck-Nielsen, H., Ed.; Springer: Berlin/Heidelberg, Germany, 2013; p. 64.
7. Sánchez, A.; Vázquez, A. Bioactive peptides: A review. *Food Qual. Saf.* 2017, 1, 29–46. [CrossRef]
8. Daliri, E.D.; Oh, D.H.; Lee, B.H. Bioactive Peptides. *Foods* 2017, 6, 32. [CrossRef]
9. Iwaniak, A.; Darewicz, M.; Minkiewicz, P. Peptides derived from foods as supportive diet components in the prevention of metabolic syndrome. *Compr. Rev. Food Sci. Food Saf.* 2017, 17, 63–81. [CrossRef]
10. Dullius, A.; Fassina, P.; Girotti, M.; Goettert, M.I.; Volken de Souza, C.F. A biotechnological approach for the production of branched chain amino acid containing bioactive peptides to improve human health: A review. *Food Res. Int.* 2020, 131, 109002. [CrossRef]
11. Lin, K.; Zhang, L.; Han, X.; Xin, L.; Meng, Z.; Gong, P.; Cheng, D. Yak milk casein as potential precursor of angiotensin I-converting enzyme inhibitory peptides based on in silico proteolysis. *Food Chem.* 2018, 254, 340–347. [CrossRef]
12. Fu, Y.; Wu, W.; Zhu, M.; Xiao, Z. In silico assessment of the potential of patatin as a precursor of bioactive peptides. *J. Food Biochem.* 2016, 40, 366–370. [CrossRef]
13. Kang, N.J.; Jin, H.S.; Lee, S.E.; Kim, H.J.; Koh, H.; Lee, D.W. New approaches toward the discovery and evaluation of bioactive peptides from natural resources. *Crit. Rev. Environ. Sci. Tec.* 2020, 1, 72–103. [CrossRef]
14. Shewry, P.R.; Napier, J.A.; Tatham, A.S. Seed storage proteins: Structures and biosynthesis. *Plant Cell* 1995, 7, 945–956. [PubMed]
15. Shewry, P.R.; Halford, N.G. Cereal seed storage proteins: Structures, properties and role in grain utilization. *J. Exp. Bot.* 2002, 53, 947–958. [CrossRef]
16. Song, M.; Fung, T.T.; Hu, F.; Willett, W.; Longo, V.; Chan, A.; Giovannucci, E. Association of animal and plant protein intake with all-cause cause-specific mortality. *JAMA Intern. Med.* 2016, 176, 1453–1463. [CrossRef]
17. Minkiewicz, P.; Dziuba, J.; Iwaniak, A.; Dziuba, M.; Darewicz, M. BIOPEP database and other programs for processing bioactive peptide sequences. J. AOAC Int. 2008, 91, 965–980. [CrossRef]
18. Gupta, S.; Kapoor, P.; Chaudhary, K.; Gautam, A.; Kumar, R.; Raghava, G. In silico approach for predicting toxicity of peptides and proteins. PLoS ONE 2013, 8, e73957. [CrossRef]
19. Ganapathy, V.; Gupta, N.; Martindale, R.G. Protein Digestion and Absorption. In Physiology of the Gastrointestinal Tract; Johnson, L.R., Ed.; Academic Press: Cambridge, MA, USA, 2006; pp. 1667–1692.
20. Kaiser, S.; Martin, M.; Lunoe, D.; Rudolph, S.; Mertten, S.; Möckel, U.; Deußgen, A.; Henle, T. Tryptophan-containing dipeptides are bioavailable and inhibit plasma human angiotensin-converting enzyme in vivo. Int. Dairy J. 2016, 52, 107–114. [CrossRef]
21. Tokunaga, K.; Yoshida, C.; Suzuki, K.; Maruyama, H.; Futamura, Y.; Araki, Y.; Mishima, S. Antihypertensive effect of peptides from royal jelly in spontaneously hypertensive rats. Biol. Pharm. Bull. 2004, 27, 189–192. [CrossRef]
22. Sato, M.; Hosokawa, T.; Yamaguchi, T.; Nakano, T.; Maramoto, K.; Kahara, T.; Funayama, K.; Kobayashi, A.; Nakano, T. Angiotensin I-converting enzyme inhibitory peptides derived from Wakame (Undaria pinnatifida) and their antihypertensive effect in spontaneously hypertensive rats. J. Agric. Food Chem. 2002, 50, 6245–6252. [CrossRef]
23. Wu, J.; Ding, X. Hypotensive and physiological effect of angiotensin converting enzyme inhibitory peptides derived from soy protein on spontaneously hypertensive rats. J. Agric. Food Chem. 2001, 49, 501–506. [CrossRef] [PubMed]
24. Xie, N.; Wang, B.; Jiang, L.; Liu, C.; Li, B. Hydrophobicity exert different effects on bioavailability and stability of antioxidant peptide fractions from casein during simulated gastrointestinal digestion and Caco-2 cell absorption. Food Res. Int. 2015, 76, 518–526. [CrossRef] [PubMed]
25. Umezawa, H.; Aoyagi, T.; Ogawa, K.; Naganawa, H.; Hamada, M.; Takeuchi, T. Diprotins A and B inhibitors of dipeptidyl aminopeptidase IV produced by bacteria. J. Antibiot. 1984, 37, 422–425. [CrossRef] [PubMed]
26. Nogoniumera, A.B.; FitzGerald, R.J. Features of dipeptidyl peptidase IV (DPPIV) inhibitory peptides from dietary proteins. J. Food Biochem. 2017, 43, e12451. [CrossRef] [PubMed]
27. Zheng, L.; Dong, H.; Su, G.; Zhao, Q.; Zhao, M. Radical scavenging activities of Tyr-, Trp, Cys, and Met-Gly and their protective effects against AAPH-induced oxidative damage in human erythrocytes. Food Chem. 2016, 197, 807–813. [CrossRef] [PubMed]
28. Fatma, Z.N.; Wahyu, B. The effect of peptide (Asp-Glu) synthetic base on sterilized fermented soymilk on lipid profile of Sprague Dawley Rats. Int. Food Res. J. 2013, 20, 3047–3052.
29. Pooj, K.; Rani, S.; Prakash, B. In silico approaches towards the exploration of rice bran proteins-derived angiotensin-I-converting enzyme inhibitory peptides. Int. J. Food Prop. 2017, 20, 2178–2191.
30. Matsui, T.; Hayashi, A.; Tamaya, K.; Matsumoto, K.; Kawasaki, T.; Mursksmi, K.; Kimoto, K. Depressor effect induced by dipeptide, Val-Tyr, in hypertensive transgenic mice is due, in part, to the suppression of human circulating renin-angiotensin system. Clin. Exp. Pharmacol. Physiol. 2003, 30, 262–265. [CrossRef]
31. Saito, Y.; Wanezaki, K.; Kawato, A.; Imayasu, S. Structure and activity of angiotensin I converting enzyme inhibitory peptides from sake and sake less. Biosci. Biotechnol. Biochem. 1994, 58, 1767–1771. [CrossRef]
32. Kahijara, R.; Shibata, K.; Nakatsu, S.; Sakamoto, K. Production of angiotensin I-converting enzyme-inhibitory peptides in a freeze-thaw infusion-treated soybean. Food Sci. Technol. Res. 2011, 17, 561–565.
33. Wu, H.; He, H.; Chen, X.; Sun, C.; Zhang, Y.; Zhou, B. Purification and identification of novel angiotensin-I-converting enzyme inhibitory peptide from shark meat hydrolysate. Process Biochem. 2008, 43, 457–461. [CrossRef]
34. Jahandideh, F.; Chakrabart, S.; Davige, S.T.; Wu, J. Antioxidant peptides identified from ovotransferrin by the ORAC method did not show anti-inflammatory and antioxidant activities in endothelial cells. J. Agric. Food Chem. 2015, 645, 113–119.
35. Chai, H.J.; Wu, C.J.; Yang, S.H.; Li, T.L.; Pan, B.S. Peptides from hydrolysate of lantern fish (Benthosema pterotum) proved neuroprotective in vitro and in vivo. J. Funct. Foods. 2016, 24, 438–449. [CrossRef]